ABIONYX Pharma Past Earnings Performance
Past criteria checks 0/6
ABIONYX Pharma's earnings have been declining at an average annual rate of -29.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 61.9% per year.
Key information
-29.7%
Earnings growth rate
-26.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 61.9% |
| Return on equity | -35.5% |
| Net Margin | -69.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ABIONYX Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -3 | 3 | 2 |
| 31 Mar 24 | 5 | -3 | 3 | 2 |
| 31 Dec 23 | 5 | -4 | 3 | 2 |
| 30 Sep 23 | 5 | -4 | 3 | 1 |
| 30 Jun 23 | 5 | -4 | 3 | 1 |
| 31 Mar 23 | 5 | -4 | 3 | 1 |
| 31 Dec 22 | 5 | -4 | 4 | 1 |
| 30 Sep 22 | 4 | -5 | 4 | 2 |
| 30 Jun 22 | 3 | -6 | 4 | 3 |
| 31 Mar 22 | 2 | -6 | 3 | 3 |
| 31 Dec 21 | 1 | -6 | 2 | 4 |
| 30 Sep 21 | 0 | -5 | 2 | 4 |
| 30 Jun 21 | 0 | -4 | 1 | 3 |
| 31 Mar 21 | 0 | -3 | 1 | 3 |
| 31 Dec 20 | 0 | -2 | 1 | 2 |
| 30 Sep 20 | 0 | -2 | 1 | 1 |
| 30 Jun 20 | 0 | -2 | 1 | 1 |
| 31 Mar 20 | 0 | 0 | 2 | 1 |
| 31 Dec 19 | 0 | 2 | 2 | 1 |
| 30 Sep 19 | 0 | 1 | 2 | 2 |
| 30 Jun 19 | 0 | 0 | 2 | 2 |
| 31 Mar 19 | 0 | -3 | 2 | 3 |
| 31 Dec 18 | 0 | -6 | 2 | 4 |
| 30 Sep 18 | 0 | -7 | 2 | 4 |
| 30 Jun 18 | 0 | -8 | 2 | 4 |
| 31 Mar 18 | 0 | -6 | 2 | 5 |
| 31 Dec 17 | 0 | -5 | 2 | 5 |
| 30 Sep 17 | 0 | -8 | 3 | 7 |
| 30 Jun 17 | 0 | -11 | 4 | 9 |
| 31 Mar 17 | 0 | -18 | 5 | 13 |
| 31 Dec 16 | 0 | -25 | 7 | 17 |
| 30 Sep 16 | 0 | -25 | 6 | 17 |
| 30 Jun 16 | 0 | -24 | 6 | 18 |
| 31 Mar 16 | 0 | -20 | 4 | 15 |
| 31 Dec 15 | 0 | -17 | 3 | 13 |
| 30 Sep 15 | 0 | -13 | 3 | 9 |
| 30 Jun 15 | 0 | -10 | 3 | 6 |
| 31 Mar 15 | 0 | -8 | 3 | 5 |
| 31 Dec 14 | 0 | -7 | 3 | 3 |
Quality Earnings: 609 is currently unprofitable.
Growing Profit Margin: 609 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 609 is unprofitable, and losses have increased over the past 5 years at a rate of 29.7% per year.
Accelerating Growth: Unable to compare 609's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 609 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 609 has a negative Return on Equity (-35.54%), as it is currently unprofitable.